Candonilimab

Generic Name: Candonilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2394841-59-7

Unique Ingredient Identifier: 6FYG1DS4NW

Background: Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Indication: 用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 3

Recruiting

Conditions: Gastric and Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: cadonilimab
Drug: pulocimab
Drug: placebo
Drug: paclitaxel

First Posted Date: 2024-04-02

Last Posted Date: 2024-06-24

Lead Sponsor: Akeso

Target Recruit Count: 506

Registration Number: NCT06341335

Locations: 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: cadonilimab

First Posted Date: 2024-04-02

Last Posted Date: 2024-04-02

Lead Sponsor: Guangzhou Institute of Respiratory Disease

Target Recruit Count: 30

Registration Number: NCT06341660

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangdong, Guangzhou, China

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: cadonilimab

First Posted Date: 2024-03-26

Last Posted Date: 2024-03-26

Lead Sponsor: Guangzhou Institute of Respiratory Disease

Target Recruit Count: 30

Registration Number: NCT06331650

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangdong, Guangzhou, China

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Phase 2

Not yet recruiting

Conditions: Melanoma

Interventions: Drug: Cadonilimab
Drug: anlotinib

First Posted Date: 2024-03-25

Last Posted Date: 2024-03-25

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06327698

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Phase 2

Not yet recruiting

Conditions: Gastric Cancer
Esophagogastric Junction Cancer

Interventions: Drug: Cadonilimab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2024-03-15

Last Posted Date: 2024-03-15

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 30

Registration Number: NCT06310473

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Phase 2

Not yet recruiting

Conditions: Cervical Cancer
Neoadjuvant Chemoimmunotherapy
Radical Hysterectomy
Extrafascial Hysterectomy

Interventions: Drug: Cadonilimab
Drug: Paclitaxel-albumin
Drug: Cisplatin
Procedure: Extrafascial hysterectomy
Procedure: Radical hysterectomy
Procedure: Cone biopsy

First Posted Date: 2024-03-04

Last Posted Date: 2024-03-04

Lead Sponsor: Tongji Hospital

Target Recruit Count: 50

Registration Number: NCT06289751

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Not Applicable

Recruiting

Conditions: Hepatocellular Carcinoma
Liver Cancer Stage IV
Bevacizumab
Cryoablation
Cadonilimab
Pulmonary Metastases

Interventions: Drug: Cadonilimab
Drug: Bevacizumab
Procedure: Cryoablation

First Posted Date: 2024-02-20

Last Posted Date: 2024-02-20

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 80

Registration Number: NCT06265350

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: AK104

First Posted Date: 2024-02-09

Last Posted Date: 2024-02-09

Lead Sponsor: West China Second University Hospital

Target Recruit Count: 50

Registration Number: NCT06251388

Locations: 🇨🇳
West China Second University Hospital, Chengdu, Sichuan, China

Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

Phase 2

Recruiting

Conditions: Neoadjuvant Immunotherapy
Fertility-sparing Surgery
Cervical Cancer

Interventions: Drug: AK104
Drug: Carboplatin
Drug: Nab paclitaxel

First Posted Date: 2024-01-17

Last Posted Date: 2024-01-17

Lead Sponsor: Xiaohua Wu

Target Recruit Count: 30

Registration Number: NCT06209294

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: RC48-ADC
Drug: AK104

First Posted Date: 2023-12-21

Last Posted Date: 2023-12-21

Lead Sponsor: Shanxi Province Cancer Hospital

Target Recruit Count: 36

Registration Number: NCT06178601

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, 北京, Beijing, China
🇨🇳
Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy